Imdur (Isosorbide Mononitrate)

After oral administration, isosorbide mononitrate is converted to nitric oxide. The nitric oxide activates guanylate cyclase, increasing cyclic GMP levels in vascular smooth muscle, which leads to relaxation of veins and arteries, lowering cardiac workload and oxygen demand.

The appropriate dose of Imdur is determined by the prescribing healthcare professional based on the individual’s clinical condition, response, and tolerance. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of isosorbide mononitrate in pregnancy or while breastfeeding has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified clinician.

To request Imdur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imdur belongs to the nitrate class, which provides rapid vasodilation and is effective for angina prophylaxis. Compared with beta‑blockers or calcium‑channel blockers, nitrates act primarily by reducing preload, and they can be combined with other agents when monotherapy is insufficient.

Imdur should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Imdur is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent blood levels.

The most serious risks include severe hypotension, syncope, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience fainting, a sudden drop in blood pressure, or severe skin rash.

Imdur is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or other nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe anemia or uncontrolled hypotension.